Twin Securities’s Revolution Medicines RVMD Stock Holding History

Twin Securities’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-38,593	Closed	-$3.75M	–	20
2026 Q1	$3.75M	Buy	+38,593	New	+$3.9M	1.82%	10

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Twin Securities's RVMD Position: Q2 2026 in Review

Twin Securities sold out of Revolution Medicines (RVMD) in Q2 2026, closing a stake of 38,593 shares — an estimated $3.75M sold.

Twin Securities first reported a position in RVMD in Q1 2026 and held it in 1 quarter. The position peaked at $3.75M in Q1 2026. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Twin Securities reported no remaining Revolution Medicines position as of Q2 2026 after selling out during the quarter.
Twin Securities sold 38,593 Revolution Medicines shares in Q2 2026, an estimated $3.75M.
Twin Securities first reported a position in Revolution Medicines in Q1 2026 and held it in 1 quarter.
Twin Securities's Revolution Medicines position peaked at $3.75M in Q1 2026.
691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Twin Securities's 13F filing for Q2 2026, filed 14 Aug 2026.